Welcome to our dedicated page for DENTSPLY SIRONA SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA (XRAY) director reported an equity change tied to restricted stock units. On 10/10/2025, the reporting person acquired 223.681 RSU dividend equivalents at $0. According to the footnote, these represent dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
Following this transaction, the reporting person beneficially owned 17,699.171 shares, held directly.
DENTSPLY SIRONA (XRAY) executive Kevin Czerney, VP and Chief Accounting Officer, reported routine equity accruals. On 10/10/2025, he acquired 233.911 RSUs as dividend equivalents at $0, which vest on the same schedule as the underlying RSUs.
Following these transactions, his direct beneficial ownership of common stock is 27,264.0691 shares. The filing notes this includes 112.5060 shares acquired through dividend reinvestment on 10/10/2025.
He was also credited 45.4596 phantom stock units under the SERP and 4.4453 phantom stock units under the DSSP at $11.98 per unit, each economically equivalent to one common share and payable in common stock upon termination of employment.
DENTSPLY SIRONA (XRAY) filed a Form 4 for director Willie A. Deese. On 10/10/2025, 179.449 restricted stock units were acquired at $0 under code A as dividend equivalents on existing RSUs. After this entry, beneficial ownership is 57,546.558 shares, held directly. These dividend RSUs follow the same vesting schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
DENTSPLY SIRONA (XRAY) reported an initial statement of beneficial ownership for executive Aldo Mariano Roberto Denti. The filing notes he serves as EVP, Chief Commercial Officer and indicates no securities are beneficially owned.
The Form 3 lists the Date of Event as 10/06/2025 and was filed by a single reporting person. An Exhibit 24 Power of Attorney is included, with the form signed by an attorney-in-fact on the executive’s behalf.
DENTSPLY SIRONA (XRAY) reported an insider transaction by SVP, CHRO Andrea Frohning. On 10/10/2025, she acquired 357.053 shares of common stock at $0, representing dividend equivalents on previously awarded RSUs that vest with their underlying awards; each RSU converts to common stock on a 1:1 basis.
She also acquired 22.893 shares of phantom stock under the Supplemental Executive Retirement Plan at a $11.98 derivative security price; phantom stock is economically equivalent to common stock and becomes payable in common stock upon termination of employment. Following these transactions, she beneficially owned 33,609.865 shares of common stock directly and 1,736.5455 phantom stock units directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) reported insider equity accruals. Officer Richard C. Rosenzweig received 766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.
He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY) reported a routine insider update: Director Janet S. Vergis acquired 179.449 additional common shares on 10/10/2025, recorded at $0, from dividend equivalents on previously granted restricted stock units (RSUs). The acquisition is coded “A.”
Following the transaction, her beneficial ownership stands at 44,300.167 common shares, held directly. The filing notes these credits reflect RSU dividend equivalents that vest on the same schedule as the related RSUs, with each RSU converting to one share.
DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.
The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.